LA JOLLA, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- MyDx Inc. (OTCBB:MYDX), a science and technology Company which created MyDx™ (My Diagnostic), the first battery operated, handheld, chemical analyzer for consumers, today announced that it has retained Investor Relations Partners (IRP) to expand the Company’s strategic investor relations program.
“2016 will be a pivotal year for MyDx and we will look towards the support and guidance of Investor Relations Partners to effectively communicate our growth story to the investment community,” said Daniel R. Yazbeck, Founder, Chairman and CEO of MyDx Inc. “We have a number of exciting developments at MyDx driven by our proprietary technology, which is designed to attract consumers from the multi-billion dollar chemical detection marketplace. Based on the increasing demand for our products within the exponentially growing consumer markets we are targetting, we expect 2016 to be a breakthrough year for MyDx and its shareholders as we continue our transition from the lab and into global commercialization,” concluded Mr. Yazbeck.
Todd Markey, Vice President of Investor Relations Partners, said, “We are looking forward to introducing the MyDx investment story to beyond its existing shareholder base and the chemical detection investment sector. We expect MyDx will appeal to both value and earnings growth retail and institutional investors given our belief that the company is significantly undervalued when considering the pent-up and growing demand for its first of a kind portable chemical analyzer product. The company’s entry into full global commercialization should enable MyDx to generate significant revenue growth and achieve profitability as early as this year,” concluded Mr. Markey.
To be added to MyDx Inc.’s investor lists, please contact Todd Markey at Investor Relations Partners at 818-280-6800 or via email at tmarkey@irpartnersinc.com.
About Investor Relations Partners, Inc.
Investor Relations Partners, Inc. (IRP) www.irpartnersinc.com is a full-service investor relations firm serving a global client base. The principals of IRP have received top industry awards for their investor relations programs for a number of high-profile companies, including, but not limited to, Starwood Hotels & Resorts Worldwide, ValueVision Media, Taro Pharmaceuticals, and LJ International. The firm's principals have executed effective investor relations programs for dozens of public companies, ranging from emerging micro-cap companies to multinational corporations with market capitalizations in excess of $15 billion. For further information on IRP, please visit the firm's Website at www.irpartnersinc.com.
About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a science and technology company based in San Diego, California whose mission is to help people Trust & Verify™ what they put into their minds and bodies. The Company has developed MyDx, an affordable portable analyzer that provides real-time chemical analysis and fits in the palm of your hands. MyDx leverages over a decade of established electronic nose technology to measure chemicals of interest and has four sensors being developed in its lab that are compatible with the MyDx Analyzer and App. For more information, please visit www.cdxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov.